International Patent Classification: A61K 31/57

International Publication Number: WO 98/50042
International Publication Date: 12 November 1998 (12.11.98)

(21) International Application Number: PCT/US98/08456
(22) International Filing Date: 28 April 1998 (28.04.98)
(30) Priority Data: 08/850,567 2 May 1997 (02.05.97) US
(72) Inventors: KAGAN, Michael, Z.; 4 Mackenzie Lane, Plainboro, NJ 08536 (US). SHAH, Syed, Muzafar; 13 Yvette Drive, East Hanover, NJ 07936 (US).


Published

With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PREGNAN-3-OL-20-ONES

(57) Abstract

This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GB</td>
<td>United Kingdom</td>
<td>LV</td>
<td>Latvia</td>
<td>SZ</td>
<td>Swaziland</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GE</td>
<td>Georgia</td>
<td>MC</td>
<td>Monaco</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslav</td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
<td>TM</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
<td>TR</td>
<td>Turkey</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
<td>YU</td>
<td>Yugoslavia</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
<td>PL</td>
<td>Poland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RO</td>
<td>Romania</td>
<td>RW</td>
<td>Rwanda</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>RU</td>
<td>Russian Federation</td>
<td>RW</td>
<td>Rwanda</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SD</td>
<td>Sudan</td>
<td>SA</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LR</td>
<td>Liberia</td>
<td>SE</td>
<td>Sweden</td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LS</td>
<td>Lesotho</td>
<td>SI</td>
<td>Slovenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LT</td>
<td>Lithuania</td>
<td>SK</td>
<td>Slovakia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td>LU</td>
<td>Luxembourg</td>
<td>SN</td>
<td>Senegal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>LV</td>
<td>Latvia</td>
<td>SZ</td>
<td>Swaziland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td>MC</td>
<td>Monaco</td>
<td>TD</td>
<td>Chad</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
<td>MG</td>
<td>Madagascar</td>
<td>TG</td>
<td>Togo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GB</td>
<td>United Kingdom</td>
<td>MK</td>
<td>The former Yugoslav</td>
<td>TJ</td>
<td>Tajikistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GE</td>
<td>Georgia</td>
<td>ML</td>
<td>Mali</td>
<td>TM</td>
<td>Turkmenistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GH</td>
<td>Ghana</td>
<td>MN</td>
<td>Mongolia</td>
<td>TR</td>
<td>Turkey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GN</td>
<td>Guinea</td>
<td>MR</td>
<td>Mauritania</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GR</td>
<td>Greece</td>
<td>MW</td>
<td>Malawi</td>
<td>UA</td>
<td>Ukraine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HU</td>
<td>Hungary</td>
<td>MX</td>
<td>Mexico</td>
<td>UG</td>
<td>Uganda</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IE</td>
<td>Ireland</td>
<td>NE</td>
<td>Niger</td>
<td>US</td>
<td>United States of America</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL</td>
<td>Israel</td>
<td>NL</td>
<td>Netherlands</td>
<td>UZ</td>
<td>Uzbekistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IS</td>
<td>Iceland</td>
<td>NO</td>
<td>Norway</td>
<td>VN</td>
<td>Viet Nam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IT</td>
<td>Italy</td>
<td>NZ</td>
<td>New Zealand</td>
<td>YU</td>
<td>Yugoslavia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JP</td>
<td>Japan</td>
<td>PL</td>
<td>Poland</td>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PREGNAN-3-OL-20-ONES

BACKGROUND OF THE INVENTION

The use of naturally occurring estrogenic compositions of substantial purity and low toxicity such as PREMARIN (conjugated equine estrogens) has become a preferred medical treatment for alleviating the symptoms of menopausal syndrome, osteoporosis/osteopenia in estrogen deficient women and in other hormone related disorders. The estrogenic components of the naturally occurring estrogenic compositions have been generally identified as sulfate esters of estrone, equilenin, 17-β-estradiol, dihydroequilenin and 17-β-dihydroequilenin (U.S. Patent 2,834,712). The estrogenic compositions are usually buffered or stabilized with alkali metal salts of organic or inorganic acids at a substantially neutral pH of about 6.5 to 7.5. Urea has also been used as a stabilizer (U.S. 3,608,077). The incorporation of antioxidants to stabilize synthetic conjugated estrogens and the failure of pH control with tris(hydroxymethyl)aminomethane (TRIS) to prevent hydrolysis is discussed in U.S. 4,154,820.

One of the compounds described herein, 5α-pregnan-3β-ol-20-one 3-sulfate ester sodium salt is a minor component of PREMARIN (conjugated equine estrogens), and is also commercially available.

DESCRIPTION OF THE INVENTION

In accordance with this invention, there is providing progestational therapy to a mammal in need thereof, which comprises administering a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal. This invention also provides a method of providing progestational therapy to a mammal in need thereof, which comprises administering a composition of matter consisting essentially of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal.

Pharmaceutically acceptable salts of 5α-pregnan-3β-ol-20-one 3-sulfate ester include, but are not limited to, the alkali metal salts, alkaline earth metal salts, ammonium salts, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group,
trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and
tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

Alkali metal salts include sodium and potassium salts, particularly preferred are
sodium salts. Alkaline earth metal salts include calcium and magnesium salts. Suitable
alkyl groups include methyl, ethyl, propyl, butyl, pentyl and hexyl, preferred alkyl
groups being methyl and ethyl. Where more than one alkyl group is present the groups
may be the same or different. Preferred trialkylammonium salts are
trimethylammonium salts and triethylammonium salts.

The present invention further provides compositions comprising
pharmacologically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester. In
particular it provides compositions comprising at least 1% of pharmacologically
acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester. One aspect of the present
invention provides compositions wherein the only progestational agent is a
pharmacologically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester. Embodiments of the present invention include compositions wherein the only active
compound is pharmacologically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate
ester. In these embodiments other excipients and carriers may be included but no
further active materials are included.

The present invention also provides a process for the preparation of a pharmacologically
acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester which comprises:

a) converting 5α-pregnan-3β-ol-20-one 3-sulfate ester to a pharmacologically
acceptable salt or

b) converting a pharmacologically acceptable salt of 5α-pregnan-3β-ol-20-one 3-
sulfate ester to a different pharmacologically acceptable salt of 5α-pregnan-3β-ol-20-one
3-sulfate ester.

5α-pregnan-3β-ol-20-one 3-sulfate esters may be converted to pharmacologically
acceptable salts by neutralising the acid with an appropriate base, e.g. with an alkali
metal carbonate, an alkaline earth metal carbonate or a primary, secondary, tertiary or
quaternary amine carbonate. Alkali metal or alkaline earth metal salts may be prepared
by using the appropriate alkali metal hydride e.g. sodium hydride, potassium hydride or lithium hydride.

A pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester may be converted to a different pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester by displacement, by using an ion exchange resin or by double decomposition (metastasis). Displacement of a weak base with a stronger one may be utilised to convert, e.g. an amine salt to an alkali metal salt or an alkaline earth metal salt using an appropriate base, e.g. a hydroxide. For example a trialkylamine salt such as a triethylamine salt may be converted to an alkali metal salt such as a sodium salt by treating it with an alkali metal hydroxide such as aqueous sodium hydroxide. The displacement may be carried out using an ion exchange resin. Alternatively one salt may be converted to another by double decomposition, e.g. an alkaline earth metal salt such as the calcium salt may be replaced with an alkali metal salt. E.g. the calcium salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester may be dissolved in water followed by the addition of e.g. sodium carbonate. Insoluble calcium carbonate would then precipitate out to provide the sodium salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester.

A pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester may be prepared by directly converting 5α-pregnan-3β-ol-20-one to a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester. This may be performed by reacting it with the appropriate aminesulfurtrioxide complex, e.g. by reacting it with a trialkylaminesulfurtrioxide (such as triethylaminesulfurtrioxide complex) to provide the corresponding trialkylamine salt (such as the triethylamine salt). If desired the salt may then be converted to another salt of the invention as described above. Alkali metal or alkaline earth metal salts may be prepared by treating 5α-pregnan-3β-ol-20-one with the appropriate alkali metal hydride e.g. sodium hydride, potassium hydride or lithium hydride to produce the corresponding alkoxide in situ and then adding a trialkylaminesulfurtrioxide (such as triethylaminesulfurtrioxide complex) to provide the corresponding trialkylamine salt (such as the triethylamine salt). If desired the salt may then be converted to another salt of the invention as described above.

The present invention also provides pharmaceutically acceptable salts of 5α-pregnan-3β-ol-20-one 3-sulfate ester prepared by a chemical process, particularly those prepared according to the processes described above. The invention also provides
pharmacologically acceptable salts of 5α-pregnan-3β-ol-20-one 3-sulfate ester obtainable by such processes.

The compounds of this invention can be prepared from readily available starting materials using standard literature techniques or can be purchased, as with 5α-pregnan-3β-ol-20-one 3-sulfate ester sodium salt.

The progestational activity of a representative compound of this invention (5α-pregnan-3β-ol-20-one 3-sulfate ester sodium salt) was evaluated in an in vitro standard pharmacological test procedure. The procedure used and results obtained are briefly described below.

The results of these standard pharmacological test procedures demonstrate that the compounds of this invention are progestational. In this test procedure, the progestational activity of a compound is quantified based on its stimulation of alkaline phosphatase enzyme activity in T47D cells, a human breast cancer cell line which expresses high levels of progesterone receptors. This is a well established test procedure in which both the progestin receptors and the response stimulated by activated progestin receptors are endogenous to the cells. Cells are pre-conditioned in low serum medium for one day and then treated with test compounds. Alkaline phosphatase activity is measured 24 hr after treatment. Reference progestins, such as progesterone and medroxyprogesterone acetate, induce a 30 - 60 fold induction of alkaline phosphatase requiring only low nanomolar concentrations for activity. The alkaline phosphatase activity induced by progestins is blocked or inhibited by progestin receptor antagonists such as RU486 indicating the specificity of the response. When evaluated in this test procedure, 5α-pregnan-3β-ol-20-one 3-sulfate ester sodium salt, had an IC$_{50}$ of 5 x 10$^{-6}$ demonstrating progestational activity.

The neuroprotective and cognition enhancing effects of the compounds of this invention were evaluated in an in vitro standard pharmacological test procedure which measured the effects of 5α-pregnan-3β-ol-20-one 3-sulfate ester sodium salt, as a representative compound of this invention, on calcium and potassium channel currents. Briefly, the following procedure was used.

Whole cell recording techniques were used to record calcium and potassium currents from cultured hippocampal neurons. The compounds to be evaluated were made fresh each day in a 400 μM ethanol stock solution. The test compounds were
diluted in saline to obtain a final concentration of 2 μM. The amplitude of calcium or potassium currents in control, test compound, and washout solutions was measured from at least 10 current traces for each condition. To compensate for rundown of the calcium current with time, control and washout currents were averaged. The current amplitude with drug was divided by the averaged control and washout current to determine the percent change. The means, standard deviations and errors for each test compound were calculated and significance from control was determined using the paired T-Test. 5α-Pregnan-3β,20β-diol enhanced increased potassium channel currents versus control by 21.76 ± 2.40 % (p = 0.0006), indicating that 5α-pregnan-3β,20β-diol hyperpolarizes neurons, thereby allowing them to respond more readily to other stimuli. Calcium channel currents were significantly decreased (p = 0.044) from control decrease by 4.64 ± 1.64 % versus control) demonstrating the neuroprotective effects of 5α-pregnan-3β-ol-20-one 3-sulfate ester sodium salt. These results show that the compounds of this invention are useful as neuroprotective agents, in protecting against epileptic seizures, and in cognition enhancement.

The compounds of this invention are progestational agents. Based on the results obtained in the standard pharmacological test procedures, the compounds of the invention are useful as oral contraceptives (male and female), in hormone replacement therapy (particularly when combined with an estrogen), in the treatment of endometriosis luteal phase defects, benign breast and prostatic diseases and prostatic and endometrial cancers. The compounds of this invention are also useful in protecting against epileptic seizures, in cognition enhancement, in treating Alzheimer’s disease, dementias, vasomotor sympotoms related to menopause, and other central nervous system disorders. The compounds of this invention are further useful in stimulating erythropoises.

The compounds of this invention can be used alone as a sole therapeutic agent or can be used in combination with other agents, such as other estrogens, progestins, or androgens.

The compounds of this invention can be formulated neat or with a pharmaceutical carrier for administration, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmacological practice. The pharmaceutical carrier may be solid or liquid.
A solid carrier can include one or more substances which may also act as
flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants,
compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating
material. In powders, the carrier is a finely divided solid which is in admixture with the
finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier
having the necessary compression properties in suitable proportions and compacted in
the shape and size desired. The powders and tablets preferably contain up to 99% of
the active ingredient. Suitable solid carriers include, for example, calcium phosphate,
magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl
cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes
and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions,
syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or
suspended in a pharmaceutically acceptable liquid carrier such as water, an organic
solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier
can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers,
buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening
agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples
of liquid carriers for oral and parenteral administration include water (partially
containing additives as above, e.g. cellulose derivatives, preferably sodium
carboxymethyl cellulose solution), alcohols (including monohydric alcohols and
polyhydric alcohols, e.g. glycols) and their derivatives, lecithins, and oils (e.g.
fractionated coconut oil and arachis oil). For parenteral administration, the carrier can
also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers
are useful in sterile liquid form compositions for parenteral administration. The liquid
carrier for pressurized compositions can be halogenated hydrocarbon or other
pharmacologically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions
can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous
injection. Sterile solutions can also be administered intravenously. The compounds of
this invention can also be administered orally either in liquid or solid composition form.

The compounds of this invention may be administered rectally or vaginally in
the form of a conventional suppository. For administration by intranasal or
intrabronchial inhalation or insufflation, the compounds of this invention may be
formulated into an aqueous or partially aqueous solution, which can then be utilized in
the form of an aerosol. The compounds of this invention may also be administered
transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.

The dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular subject being treated. Based on the results obtained in the standard pharmacological test procedures, projected daily dosages of active compound would be 0.02 µg/kg - 750 µg/kg. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached; precise dosages for oral, parenteral, nasal, or intrabronchial administration will be determined by the administering physician based on experience with the individual subject treated. Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
WHAT IS CLAIMED IS:

1. A method of providing progesterational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregn-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.

2. The method according to claim 1, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

3. A method of treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease in a mammal in need thereof, which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregn-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.

4. The method according to claim 3, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

5. A method of providing progesterational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a composition of matter consisting essentially of a pharmaceutically acceptable salt of 5α-pregn-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.

6. The method according to claim 5, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.
7. A method of treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease in a mammal in need thereof, which comprises administering a progestationally effective amount of a composition of matter consisting essentially of a pharmaceutically acceptable salt of 5\alpha-pregnan-3\beta-ol-20-one 3-sulfate ester to said mammal to said mammal.

8. The method according to claim 7, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

9. A method of providing cognition enhancement to a mammal in need thereof which comprises administering a cognition enhancement effective amount of a pharmaceutically acceptable salt of 5\alpha-pregnan-3\beta-ol-20-one 3-sulfate ester to said mammal to said mammal.

10. The method according to claim 9, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

11. Use of a pharmaceutically acceptable salt of 5\alpha-pregnan-3\beta-ol-20-one 3-sulfate ester as a medicament.

12. Use of a pharmaceutically acceptable salt of 5\alpha-pregnan-3\beta-ol-20-one 3-sulfate ester in the preparation of a medicament for:
   a) providing progestational therapy,
   b) treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease or
   c) providing cognition enhancement
to a mammal in need thereof.
13. A process for the preparation of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester which comprises:

a) converting 5α-pregnan-3β-ol-20-one 3-sulfate ester to a pharmaceutically acceptable salt or

b) converting a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to a different pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester.

14. A process for the preparation of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester which comprises the direct conversion of 5α-pregnan-3β-ol-20-one.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/57

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>IRWIN R P ET AL: &quot;STEROID POTENTIATION AND INHIBITION OF N-METHYL-D-ASPARTATE RECEPTOR-MEDIATED INTRACELLULAR CA++ RESPONSES: STRUCTURE-ACTIVITY STUDIES&quot; JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 271, no. 2, November 1994, pages 677-682, XP000609600 see page 677, column 1, paragraph 2 - column 2, paragraph 1 see page 681, column 1, paragraph 3</td>
<td>3,4,7-12</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

Date of the actual completion of the international search

21 September 1998

Date of mailing of the international search report

01/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-3040, Tx. 31 651 epos nl, Fax (+31-70) 340-3016

Authorized officer

A. Jakobs

From PCT/ISA210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>MIJEONG PARK-CHUNG ET AL: &quot;3ALPHA-HYDROXY-5BETA-PREGNAN-20-ONE SULFATE: A NEGATIVE MODULATOR OF THE NMDA-INDUCED CURRENT IN CULTURED NEURONS&quot; MOLECULAR PHARMACOLOGY, vol. 46, no. 1, July 1994, pages 146-150, XP000609601 see abstract see page 146, column 1, paragraph 3 - column 2, paragraph 1 see page 149, column 2, paragraph 7 - page 150, column 1, paragraph 2</td>
<td>3, 4, 7-12</td>
</tr>
<tr>
<td>X</td>
<td>TOWNSLEY, J.D.: &quot;Further Studies on the Regulation of Human Placental Steroid 3-Sulfatase Activity&quot; ENDOCRINOLOGY, 1972, pages 172-181, XP0002076176 see page 172, column 1, paragraph 1 - column 2, paragraph 1</td>
<td>13, 14</td>
</tr>
<tr>
<td>X</td>
<td>BAILLIE ET AL.: &quot;SYNTHESIS OF SPECIFICALLY DEUTERIUM-LABELLED PREGNANOLONE AND PREGNANEDIOL SULPHATES FOR METABOLIC STUDIES IN HUMANS&quot; STEROIDS, vol. 26, no. 4, 1975, pages 438-457, XP0002076218 see page 442, paragraph 5 - page 443, paragraph 1</td>
<td>14</td>
</tr>
<tr>
<td>X,P</td>
<td>MIJEONG PARK-CHUNG ET AL.: &quot;Distinct Sites for Inverse Modulation of N-Methyl-D-Aspartate Receptors by Sulfated Steroids&quot; MOL. PHARM., vol. 52, no. 6, 1997, pages 1113-1123, XP0002076175 see page 1113, column 1, paragraph 1 - column 2, paragraph 1 see page 1122, column 2, paragraph 2 - paragraph 4; table 1</td>
<td>3, 4, 7-12</td>
</tr>
</tbody>
</table>

Form PCT/ISA/219 (continuation of second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>BITRAN D ET AL: &quot;ANXIOLYTIC EFFECT OF 3A-HYDROXY 5A BETA-PREGNAN-20-ONE: ENDOGENOUS METABOLITES OF PROGESTERONE THAT ARE ACTIVE AT THE GABAA RECEPTOR&quot; BRAIN RESEARCH, vol. 561, no. 1, 4 October 1991, pages 157-161, XP002050235 see page 335, column 2, paragraph 3 see page 336, column 2, paragraph 1 see page 337, column 2, paragraph 2: figure 2</td>
<td>1-14</td>
</tr>
<tr>
<td>A</td>
<td>MICKAN ET AL.: &quot;PREGNANOLONES AND PREGNENOLONE IN HUMAN MYOMETRIUM AT TERM OF PREGNANCY&quot; J. STEROID BIOCHEM., vol. 11, no. 4, 1979, pages 1455-1459, XP002076219 see the whole document</td>
<td>1-12</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 1-10
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 1-10 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.: 1-10
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:

3. [ ] Claims Nos.: 1-10
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.